Current clinical practice guidelines for the management of renal cell carcinoma (RCC) include those produced by the European Society for Medical Oncology (ESMO)12, the European Association of Urology (EAU) 13, and the National Comprehensive Cancer Network (NCCN) 15, updated in 2019.
Cabometyx and the ESMO RCC Guidelines
The only TKI to be given a ‘Grade A’ recommendation in patients who have received prior TKI therapy [I,A] and treatment-naïve patients (intermediate-risk) [II,A]
For more info about the latest ESMO clinical practice guidelines on the diagnosis, treatment and follow-up of renal cell carcinoma:
Cabometyx and the EAU RCC Guidelines
Read about the 2019 update of the EAU guidelines on renal cell carcinoma.
Cabometyx and the NCCN RCC Guidelines
The only TKI to be designated as “preferred” in treatment-naïve patients (intermediate-, poor-risk) and those who have received prior therapy
For more info about NCCN clinical practice guidelines on renal cell carcinoma: